Περίληψη:
The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This first part of the guideline includes general information on its scope and purpose, the health questions covered, target users and a methods section. It also provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for paediatric, adolescent, pregnant and breastfeeding patients. © 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Συγγραφείς:
Wollenberg, A.
Kinberger, M.
Arents, B.
Aszodi, N.
Avila Valle, G.
Barbarot, S.
Bieber, T.
Brough, H.A.
Calzavara Pinton, P.
Christen-Zäch, S.
Deleuran, M.
Dittmann, M.
Dressler, C.
Fink-Wagner, A.H.
Fosse, N.
Gáspár, K.
Gerbens, L.
Gieler, U.
Girolomoni, G.
Gregoriou, S.
Mortz, C.G.
Nast, A.
Nygaard, U.
Redding, M.
Rehbinder, E.M.
Ring, J.
Rossi, M.
Serra-Baldrich, E.
Simon, D.
Szalai, Z.Z.
Szepietowski, J.C.
Torrelo, A.
Werfel, T.
Flohr, C.
Λέξεις-κλειδιά:
abrocitinib; alitretinoin; azathioprine; baricitinib; calcineurin inhibitor; corticosteroid; cyclosporine; dupilumab; glucocorticoid; immunoglobulin; Janus kinase; lebrikizumab; methotrexate; mycophenolate mofetil; mycophenolic acid; nemolizumab; omalizumab; placebo; prednisolone; tralokinumab; upadacitinib; azathioprine; cyclosporine; immunosuppressive agent, abdominal pain; acne; allergy; anaphylaxis; anemia; arthralgia; Article; asthma; atopic dermatitis; bone marrow toxicity; chronic spontaneous urticaria; comorbidity; conjunctivitis; connective tissue disease; consensus development; diabetes mellitus; disease management; drug contraindication; drug dose comparison; drug efficacy; drug mechanism; drug safety; elevated blood pressure; eosinophilia; Europe; evidence based practice; fatigue; fever; fibrosing alveolitis; gastritis; gastrointestinal symptom; headache; helminthiasis; herpes simplex; herpes virus infection; herpes zoster; human; hyperglycemia; hypertransaminasemia; infection; injection site reaction; leukopenia; liver toxicity; low drug dose; musculoskeletal disease; myalgia; nausea; neutropenia; nonhodgkin lymphoma; nonhuman; osteoporosis; pancreatitis; pancytopenia; peptic ulcer; peripheral edema; phototherapy; practice guideline; pregnancy; rheumatoid arthritis; rhinopharyngitis; rigor; side effect; skin atrophy; sleep disorder; squamous cell skin carcinoma; systemic therapy; thrombocytopenia; thrombocytosis; upper respiratory tract infection; adolescent; atopic dermatitis; child; eczema, Adolescent; Azathioprine; Child; Cyclosporine; Dermatitis, Atopic; Eczema; Humans; Immunosuppressive Agents; Mycophenolic Acid
